The delicate balance of graft versus leukemia and graft versus host disease after allogeneic hematopoietic stem cell transplantation

References

• Cieri N, Maurer K, Wu CJ. 60 years young: the evolving role of allogeneic hematopoietic stem cell transplantation in Cancer immunotherapy. Cancer Res. 2021 Sep 1;81(17):4373–4384. doi: 10.1158/0008-5472.CAN-21-0301
   PubMed Web of Science ®Google Scholar
• Schmid C, Labopin M, Nagler A, et al. Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 2012 Feb 9;119(6):1599–1606. doi: 10.1182/blood-2011-08-375840
   PubMed Web of Science ®Google Scholar
• Collins RH Jr., Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol. 1997 Feb;15(2):433–444. doi: 10.1200/JCO.1997.15.2.433
   PubMed Web of Science ®Google Scholar
• Mo XD, Xu LP, Zhang XH, et al. Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome. Bone Marrow Transplant. 2015 1;50(1):127–133. doi: 10.1038/bmt.2014.223
   PubMed Web of Science ®Google Scholar
• Buxbaum NP, Socié G, Hill GR, et al. Chronic GvHD NIH consensus project biology task force: evolving path to personalized treatment of chronic GvHD. Blood Adv. 2022 Nov 2;7(17):4886–4902.
   PubMed Web of Science ®Google Scholar
• Hanash AM, Kappel LW, Yim NL, et al. Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL. Blood. 2011 Jul 14;118(2):446–455. doi: 10.1182/blood-2010-07-294785
   PubMed Web of Science ®Google Scholar
• Miller JS, Warren EH, van den Brink MRM, et al. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biology underlying recurrence of malignant disease following allogeneic HSCT: graft-versus-tumor/Leukemia reaction. Biol Blood Marrow Transplant. 2010 5;16(5):565–586. doi: 10.1016/j.bbmt.2010.02.005
   PubMed Web of Science ®Google Scholar
• Valenzuela JO, Iclozan C, Hossain MS, et al. Pkctheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice. J Clin Invest. 2009 12;119(12):3774–3786. doi: 10.1172/JCI39692
   PubMed Web of Science ®Google Scholar
• Blazar BR, Taylor PA, Panoskaltsis-Mortari A, et al. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines. J Immunol. 1998 Jun 1;160(11):5355–5365. doi: 10.4049/jimmunol.160.11.5355
   PubMed Web of Science ®Google Scholar
• Chakupurakal G, Freudenberger P, Skoetz N, et al. Polyclonal anti-thymocyte globulins for the prophylaxis of graft-versus-host disease after allogeneic stem cell or bone marrow transplantation in adults. Cochrane Database Syst Rev. 2023 Jun 21;2023(6):CD009159. doi: 10.1002/14651858.CD009159.pub3
   Google Scholar
• Forcade E, Chevret S, Finke J, et al. Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2022 5;57(5):768–774. doi: 10.1038/s41409-022-01620-x
   PubMed Web of Science ®Google Scholar
• Du ZZ, Zhou M, Ling J, et al. PD-1 Checkpoint Blockade in Patients for Acute Myeloid Leukemia after HSCT Relapse Resulted in Severe GVHD and sHLH. Case Rep Hematol. 2022 Dec 22;2022:1705905. doi: 10.1155/2022/1705905
   PubMed Web of Science ®Google Scholar
• Schroeder T, Stelljes M, Christopeit M, et al. Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the azalena-trial. Haematologica. 2023 Jun 1. doi: 10.3324/haematol.2022.282570
   Web of Science ®Google Scholar
• Kekre N, Kim HT, Thanarajasingam G, et al. Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. Haematologica. 2015 Sep;100(9):1222–1227. doi: 10.3324/haematol.2015.129650
   PubMed Web of Science ®Google Scholar
• Thanarajasingam G, Kim HT, Cutler C, et al. Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Dec;19(12):1713–1718. doi: 10.1016/j.bbmt.2013.09.011
   PubMed Web of Science ®Google Scholar
• Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990 Feb 1;75(3):555–562. doi: 10.1182/blood.V75.3.555.555
   PubMed Web of Science ®Google Scholar
• Tomblyn MB, Arora M, Baker KS, et al. Myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia: analysis of graft sources and long-term outcome. J Clin Oncol. 2009 Aug 1;27(22):3634–3641. doi: 10.1200/JCO.2008.20.2960
   PubMed Web of Science ®Google Scholar
• Kato M, Kurata M, Kanda J, et al. Impact of graft-versus-host disease on relapse and survival after allogeneic stem cell transplantation for pediatric leukemia. Bone Marrow Transplant. 2019 1;54(1):68–75. doi: 10.1038/s41409-018-0221-6
   PubMed Web of Science ®Google Scholar
• Nordlander A, Mattsson J, Ringdén O, et al. Graft-versus-host disease is associated with a lower relapse incidence after hematopoietic stem cell transplantation in patients with acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2004 3;10(3):195–203. doi: 10.1016/j.bbmt.2003.11.002
   PubMed Web of Science ®Google Scholar
• Kanda J, Hishizawa M, Utsunomiya A, et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia: a retrospective cohort study. Blood. 2012 Mar 1;119(9):2141–2148. doi: 10.1182/blood-2011-07-368233
   PubMed Web of Science ®Google Scholar
• Itonaga H, Iwanaga M, Aoki K, et al. Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: a nationwide retrospective study. Leuk Res. 2016 Feb;41:48–55.
   PubMed Web of Science ®Google Scholar
• Hiramoto N, Kurosawa S, Tajima K, et al. Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients. Eur J Haematol. 2014 Feb;92(2):137–146. doi: 10.1111/ejh.12214
   PubMed Web of Science ®Google Scholar
• Valcarcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol. 2008 Feb 1;26(4):577–584. doi: 10.1200/JCO.2007.11.1641
   PubMed Web of Science ®Google Scholar
• Thepot S, Zhou J, Perrot A, et al. The graft-versus-leukemia effect is mainly restricted to NIH-defined chronic graft-versus-host disease after reduced intensity conditioning before allogeneic stem cell transplantation. Leukemia. 2010 Nov;24(11):1852–1858. doi: 10.1038/leu.2010.187
   PubMed Web of Science ®Google Scholar
• Dickinson AM, Norden J, Li S, et al. Graft-versus-leukemia effect following hematopoietic stem cell transplantation for leukemia. Front Immunol. 2017 Jun 7;8:496. doi: 10.3389/fimmu.2017.00496
   PubMed Web of Science ®Google Scholar
• Markey KA, MacDonald KPA, Hill GR. The biology of graft-versus-host disease: experimental systems instructing clinical practice. Blood. 2014 Jul 17;124(3):354–362. doi: 10.1182/blood-2014-02-514745
   PubMed Web of Science ®Google Scholar
• Barnes DW, Corp MJ, Loutit JF, et al. Treatment of murine leukaemia with X rays and homologous bone marrow; preliminary communication. Br Med J. 1956 Sep 15;2(4993):626–627. doi: 10.1136/bmj.2.4993.626
   PubMedGoogle Scholar
• Cooke KR, Luznik L, Sarantopoulos S, et al. The biology of chronic graft-versus-host disease: a task force report from the national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2017 Feb;23(2):211–234. doi: 10.1016/j.bbmt.2016.09.023
   PubMed Web of Science ®Google Scholar
• Zhao D, Young JS, Chen YH, et al. Alloimmune response results in expansion of autoreactive donor CD4+ T cells in transplants that can mediate chronic graft-versus-host disease. J Immunol. 2011 Jan 15;186(2):856–868. doi: 10.4049/jimmunol.1002195
   PubMed Web of Science ®Google Scholar
• Zeiser R, Blazar BR, Longo DL. Pathophysiology of chronic graft-versus-host disease and Therapeutic targets. N Engl J Med. 2017 Dec 28;377(26):2565–2579.
   PubMed Web of Science ®Google Scholar
• Yamakawa T, Ohigashi H, Hashimoto D, et al. Vitamin A-coupled liposomes containing siRNA against HSP47 ameliorate skin fibrosis in chronic graft-versus-host disease. Blood. 2018 Mar 29;131(13):1476–1485. doi: 10.1182/blood-2017-04-779934
   PubMed Web of Science ®Google Scholar
• Du J, Paz K, Flynn R, et al. Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production. Blood. 2017 May 4;129(18):2570–2580. doi: 10.1182/blood-2017-01-758854
   PubMed Web of Science ®Google Scholar
• McCormick LL, Zhang Y, Tootell E, et al. Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: a model for human scleroderma. J Immunol. 1999 Nov 15;163(10):5693–5699. doi: 10.4049/jimmunol.163.10.5693
   PubMed Web of Science ®Google Scholar
• Taylor DK, Mittereder N, Kuta E, et al. T follicular helper-like cells contribute to skin fibrosis. Sci Transl Med. 2018 Mar 7;10(431). doi: 10.1126/scitranslmed.aaf5307
   PubMed Web of Science ®Google Scholar
• Hess NJ, Turicek DP, Riendeau J, et al. Inflammatory CD4/CD8 double-positive human T cells arise from reactive CD8 T cells and are sufficient to mediate GVHD pathology. Sci Adv. 2023 Mar 24;9(12):eadf0567. doi: 10.1126/sciadv.adf0567
   PubMed Web of Science ®Google Scholar
• Biedermann BC, Sahner S, Gregor M, et al. Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease. Lancet. 2002 Jun 15;359(9323):2078–2083. doi: 10.1016/S0140-6736(02)08907-9
   PubMed Web of Science ®Google Scholar
• Sato M, Tokuda N, Fukumoto T, et al. Immunohistopathological study of the oral lichenoid lesions of chronic GVHD. J Oral Pathol Med. 2006 Jan;35(1):33–36. doi: 10.1111/j.1600-0714.2005.00372.x
   PubMed Web of Science ®Google Scholar
• Tsai JJ, Velardi E, Shono Y, et al. Nrf2 regulates CD4 T cell-induced acute graft-versus-host disease in mice. Blood. 2018 Dec 27;132(26):2763–2774. doi: 10.1182/blood-2017-10-812941
   PubMed Web of Science ®Google Scholar
• Cadwell K, Patel KK, Maloney NS, et al. Virus-plus-susceptibility gene interaction determines Crohn’s disease gene Atg16L1 phenotypes in intestine. Cell. 2010 Jun 25;141(7):1135–1145. doi: 10.1016/j.cell.2010.05.009
   PubMed Web of Science ®Google Scholar
• Cadwell K, Liu JY, Brown SL, et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal paneth cells. Nature. 2008 Nov 13;456(7219):259–263. doi: 10.1038/nature07416
   PubMed Web of Science ®Google Scholar
• Hubbard-Lucey VM, Shono Y, Maurer K, et al. Autophagy gene Atg16L1 prevents lethal T cell alloreactivity mediated by dendritic cells. Immunity. 2014 Oct 16;41(4):579–591. doi: 10.1016/j.immuni.2014.09.011
   PubMed Web of Science ®Google Scholar
• Docampo MD, da Silva MB, Lazrak A, et al. Alloreactive T cells deficient of the short-chain fatty acid receptor GPR109A induce less graft-versus-host disease. Blood. 2022 Apr 14;139(15):2392–2405. doi: 10.1182/blood.2021010719
   PubMed Web of Science ®Google Scholar
• Lu SX, Alpdogan O, Lin J, et al. STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease. Blood. 2008 Dec 15;112(13):5254–5258. doi: 10.1182/blood-2008-03-147322
   PubMed Web of Science ®Google Scholar
• Andrlová H, Miltiadous O, Kousa AI, et al. MAIT and Vδ2 unconventional T cells are supported by a diverse intestinal microbiome and correlate with favorable patient outcome after allogeneic HCT. Sci Transl Med. 2022 May 25;14(646):eabj2829. doi: 10.1126/scitranslmed.abj2829
   PubMed Web of Science ®Google Scholar
• Zorn E, Kim HT, Lee SJ, et al. Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 2005 Oct 15;106(8):2903–2911. doi: 10.1182/blood-2005-03-1257
   PubMed Web of Science ®Google Scholar
• McDonald-Hyman C, Flynn R, Panoskaltsis-Mortari A, et al. Therapeutic regulatory T-cell adoptive transfer ameliorates established murine chronic GVHD in a CXCR5-dependent manner. Blood. 2016 Aug 18;128(7):1013–1017. doi: 10.1182/blood-2016-05-715896
   PubMed Web of Science ®Google Scholar
• Landwehr-Kenzel S, Müller-Jensen L, Kuehl J-S, et al. Adoptive transfer of ex vivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD. Mol Ther. 2022 Jun 1;30(6):2298–2314. doi: 10.1016/j.ymthe.2022.02.025
   PubMed Web of Science ®Google Scholar
• Zorn E, Mohseni M, Kim H, et al. Combined CD4+ donor lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009 3;15(3):382–388. doi: 10.1016/j.bbmt.2008.12.494
   PubMed Web of Science ®Google Scholar
• Theil A, Tuve S, Oelschlägel U, et al. Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease. Cytotherapy. 2015 4;17(4):473–486. doi: 10.1016/j.jcyt.2014.11.005
   PubMed Web of Science ®Google Scholar
• Sarantopoulos S, Stevenson KE, Kim HT, et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res. 2007 Oct 15;13(20):6107–6114. doi: 10.1158/1078-0432.CCR-07-1290
   PubMed Web of Science ®Google Scholar
• Sarantopoulos S, Stevenson KE, Kim HT, et al. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009 Apr 16;113(16):3865–3874. doi: 10.1182/blood-2008-09-177840
   PubMed Web of Science ®Google Scholar
• Jacobson CA, Sun L, Kim HT, et al. Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2014 5;20(5):668–675. doi: 10.1016/j.bbmt.2014.01.021
   PubMed Web of Science ®Google Scholar
• Allen JL, Fore MS, Wooten J, et al. B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways. Blood. 2012 Sep 20;120(12):2529–2536. doi: 10.1182/blood-2012-06-438911
   PubMed Web of Science ®Google Scholar
• Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005 Apr 1;105(7):2973–2978. doi: 10.1182/blood-2004-09-3660
   PubMed Web of Science ®Google Scholar
• Miklos DB, Kim HT, Zorn E, et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood. 2004 Jan 1;103(1):353–359. doi: 10.1182/blood-2003-03-0984
   PubMed Web of Science ®Google Scholar
• Porcheray F, Miklos DB, Floyd BH, et al. Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation. Transplantation. 2011 Aug 15;92(3):359–365. doi: 10.1097/TP.0b013e3182244cc3
   PubMed Web of Science ®Google Scholar
• Zorn E, Miklos DB, Floyd BH, et al. Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. J Exp Med. 2004 Apr 19;199(8):1133–1142. doi: 10.1084/jem.20031560
   PubMed Web of Science ®Google Scholar
• Jenq RR, Ubeda C, Taur Y, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med. 2012 May 7;209(5):903–911. doi: 10.1084/jem.20112408
   PubMed Web of Science ®Google Scholar
• Jenq RR, Taur Y, Devlin SM, et al. Intestinal blautia is associated with reduced death from graft-versus-host disease. Biol Blood Marrow Transplant. 2015 8;21(8):1373–1383. doi: 10.1016/j.bbmt.2015.04.016
   PubMed Web of Science ®Google Scholar
• Shono Y, Docampo MD, Peled JU, et al. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med. 2016 May 18;8(339):339ra71. doi: 10.1126/scitranslmed.aaf2311
   PubMed Web of Science ®Google Scholar
• Burgos da Silva M, Ponce DM, Dai A, et al. Preservation of the fecal microbiome is associated with reduced severity of graft-versus-host disease. Blood. 2022 Dec 1;140(22):2385–2397. doi: 10.1182/blood.2021015352
   PubMedGoogle Scholar
• Wang Y, Huang L, Huang T, et al. The gut bacteria dysbiosis contributes to chronic graft-versus-host disease associated with a Treg/Th1 ratio imbalance. Front Microbiol. 2022;13:813576. doi: 10.3389/fmicb.2022.813576
   PubMed Web of Science ®Google Scholar
• Markey KA, Gomes AL, Littmann ER, et al. Pre-transplant and peri-d100 gastrointestinal dysbiosis is associated with the subsequent development of chronic graft-versus-host disease. Blood. 2018;132(Supplement 1):359–359. doi: 10.1182/blood-2018-99-110309
   Google Scholar
• Markey KA, Schluter J, Gomes ALC, et al. The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD. Blood. 2020 Jul 2;136(1):130–136. doi: 10.1182/blood.2019003369
   PubMed Web of Science ®Google Scholar
• Koehn BH, Zeiser R, Blazar BR. Inflammasome effects in GvHD. Oncotarget. 2015 Nov 17;6(36):38444–38445. doi: 10.18632/oncotarget.6307
   PubMedGoogle Scholar
• Broz P, Dixit VM. Inflammasomes: mechanism of assembly, regulation and signalling. Nat Rev Immunol. 2016 7;16(7):407–420. doi: 10.1038/nri.2016.58
   PubMed Web of Science ®Google Scholar
• Okin D, Kagan JC. Inflammasomes as regulators of non-infectious disease. Semin Immunol. 2023 Sep 1;69:101815. doi: 10.1016/j.smim.2023.101815
   PubMed Web of Science ®Google Scholar
• Jankovic D, Ganesan J, Bscheider M, et al. The Nlrp3 inflammasome regulates acute graft-versus-host disease. J Exp Med. 2013 Sep 23;210(10):1899–1910. doi: 10.1084/jem.20130084
   PubMed Web of Science ®Google Scholar
• Zeiser R, Penack O, Holler E, et al. Danger signals activating innate immunity in graft-versus-host disease. J Mol Med. 2011 9;89(9):833–845. doi: 10.1007/s00109-011-0767-x
   PubMed Web of Science ®Google Scholar
• Koehn BH, Apostolova P, Haverkamp JM, et al. GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells. Blood. 2015 Sep 24;126(13):1621–1628. doi: 10.1182/blood-2015-03-634691
   PubMed Web of Science ®Google Scholar
• Seike K, Kiledal A, Fujiwara H, et al. Ambient oxygen levels regulate intestinal dysbiosis and GVHD severity after allogeneic stem cell transplantation. Immunity. 2023 Feb 14;56(2):353–368.e6. doi: 10.1016/j.immuni.2023.01.007
   PubMed Web of Science ®Google Scholar
• Takahashi H, Okayama N, Yamaguchi N, et al. Associations of interactions between NLRP3 SNPs and HLA mismatch with acute and extensive chronic graft-versus-host diseases. Sci Rep. 2017 Oct 12;7(1):13097. doi: 10.1038/s41598-017-13506-w
   PubMedGoogle Scholar
• Watkins B, Qayed M, McCracken C, et al. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD. J Clin Oncol. 2021 Jun 10;39(17):1865–1877. doi: 10.1200/JCO.20.01086
   PubMed Web of Science ®Google Scholar
• van Besien K, Kunavakkam R, Rondon G, et al. Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes. Biol Blood Marrow Transplant. 2009 May;15(5):610–617. doi: 10.1016/j.bbmt.2009.01.021
   PubMed Web of Science ®Google Scholar
• Chakraverty R, Orti G, Roughton M, et al. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution. Blood. 2010 Oct 21;116(16):3080–3088. doi: 10.1182/blood-2010-05-286856
   PubMed Web of Science ®Google Scholar
• Sauter CS, Chou JF, Papadopoulos EB, et al. A prospective study of an alemtuzumab containing reduced-intensity allogeneic stem cell transplant program in patients with poor-risk and advanced lymphoid malignancies. Leuk Lymphoma. 2014 Dec;55(12):2739–2747. doi: 10.3109/10428194.2014.894185
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, Kim HT, McGuirk J, et al. Prospective, randomized, Double-blind, phase III clinical trial of anti–T-Lymphocyte globulin to assess impact on chronic graft-versus-host disease–free survival in patients undergoing HLA-Matched unrelated myeloablative hematopoietic cell transplantation. J Clin Oncol. 2017 Dec 20;35(36):4003–4011. doi: 10.1200/JCO.2017.75.8177
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001 Nov 15;98(10):2942–2947. doi: 10.1182/blood.V98.10.2942
   PubMed Web of Science ®Google Scholar
• Walker I, Panzarella T, Couban S, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016 Feb;17(2):164–173. doi: 10.1016/S1470-2045(15)00462-3
   PubMed Web of Science ®Google Scholar
• Wang Y, Fu HX, Liu DH, et al. Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial. Bone Marrow Transplant. 2014 Mar;49(3):426–433. doi: 10.1038/bmt.2013.191
   PubMed Web of Science ®Google Scholar
• Kroger N, Solano C, Wolschke C, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016 Jan 7;374(1):43–53. doi: 10.1056/NEJMoa1506002
   PubMed Web of Science ®Google Scholar
• Chang YJ, Wu DP, Lai YR, et al. Antithymocyte globulin for matched sibling donor transplantation in patients with hematologic malignancies: a multicenter, open-label, randomized controlled study. J Clin Oncol. 2020 Oct 10;38(29):3367–3376. doi: 10.1200/JCO.20.00150
   PubMed Web of Science ®Google Scholar
• Finke J, Schmoor C, Bethge WA, et al. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. Biol Blood Marrow Transplant. 2012 Nov;18(11):1716–1726. doi: 10.1016/j.bbmt.2012.06.001
   PubMed Web of Science ®Google Scholar
• Bryant A, Mallick R, Huebsch L, et al. Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017 Dec;23(12):2096–2101. doi: 10.1016/j.bbmt.2017.08.007
   PubMed Web of Science ®Google Scholar
• Zuckermann J, Castro BM, Cunha TA, et al. Systematic review and meta-analysis of anti-thymocyte globulin dosage as a component of graft-versus-host disease prophylaxis. PLoS One. 2023;18(4):e0284476. doi: 10.1371/journal.pone.0284476
   PubMed Web of Science ®Google Scholar
• Kekre N, Antin JH. ATG in allogeneic stem cell transplantation: standard of care in 2017? Counterpoint Blood Adv. 2017 Mar 28;1(9):573–576.
   PubMedGoogle Scholar
• Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-Cell–depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med. 1998 Oct 22;339(17):1186–1193. doi: 10.1056/NEJM199810223391702
   PubMed Web of Science ®Google Scholar
• Wagner JE, Donnenberg AD, Noga SJ, et al. Lymphocyte depletion of donor bone marrow by counterflow centrifugal elutriation: results of a phase I clinical trial. Blood. 1988 Oct;72(4):1168–1176. doi: 10.1182/blood.V72.4.1168.1168
   PubMed Web of Science ®Google Scholar
• Filipovich AH, McGlave PB, Ramsay NK, et al. Pretreatment of donor bone marrow with monoclonal antibody OKT3 for prevention of acute graft-versus-host disease in allogeneic histocompatible bone-marrow transplantation. Lancet. 1982 Jun 5;1(8284):1266–1269. doi: 10.1016/S0140-6736(82)92840-9
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, Murray C, Mauch P, et al. Prevention of graft-versus-host disease by selective depletion of CD6-positive T lymphocytes from donor bone marrow. J Clin Oncol. 1992 Jul;10(7):1191–1200. doi: 10.1200/JCO.1992.10.7.1191
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, Weller E, Alyea EP, et al. CD6+ donor marrow T-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors. J Clin Oncol. 2001 Feb 15;19(4):1152–1159. doi: 10.1200/JCO.2001.19.4.1152
   PubMed Web of Science ®Google Scholar
• Martin PJ, Hansen JA, Buckner CD, et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood. 1985 Sep;66(3):664–672. doi: 10.1182/blood.V66.3.664.664
   PubMed Web of Science ®Google Scholar
• Vallera DA, Ash RC, Zanjani ED, et al. Anti-T-cell reagents for human bone marrow transplantation: ricin linked to three monoclonal antibodies. Science. 1983 Nov 4;222(4623):512–515. doi: 10.1126/science.6353579
   PubMed Web of Science ®Google Scholar
• Mitsuyasu RT, Champlin RE, Gale RP, et al. Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. a prospective, randomized, double-blind trial. Ann Intern Med. 1986 Jul;105(1):20–26. doi: 10.7326/0003-4819-105-1-20
   PubMed Web of Science ®Google Scholar
• Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of HLA-identical transplants in leukemia. Blood. 1991 Oct 15;78(8):2120–2130. doi: 10.1182/blood.V78.8.2120.2120
   PubMed Web of Science ®Google Scholar
• Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988 Jun;108(6):806–814. doi: 10.7326/0003-4819-108-6-806
   PubMed Web of Science ®Google Scholar
• Marks DI, Hughes TP, Szydlo R, et al. HLA-identical sibling donor bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: influence of GVHD prophylaxis on outcome. Br J Haematol. 1992 Jul;81(3):383–390. doi: 10.1111/j.1365-2141.1992.tb08244.x
   PubMed Web of Science ®Google Scholar
• Remberger M, Ringden O, Aschan J, et al. Long-term follow-up of a randomized trial comparing T-cell depletion with a combination of methotrexate and cyclosporine in adult leukemic marrow transplant recipients. Transplant Proc. 1994 Jun;26(3):1829–1830.
   PubMed Web of Science ®Google Scholar
• Keever-Taylor CA, Devine SM, Soiffer RJ, et al. Characteristics of CliniMACS(R) system CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant clinical trials network (BMT CTN) protocol 0303. Biol Blood Marrow Transplant. 2012 May;18(5):690–697. doi: 10.1016/j.bbmt.2011.08.017
   PubMed Web of Science ®Google Scholar
• Luznik L, Pasquini MC, Logan B, et al. Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease Interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies. J Clin Oncol. 2022 Feb 1;40(4):356–368. doi: 10.1200/JCO.21.02293
   PubMed Web of Science ®Google Scholar
• Bleakley M, Sehgal A, Seropian S, et al. Naive T-Cell depletion to prevent chronic graft-versus-host disease. J Clin Oncol. 2022 Apr 10;40(11):1174–1185. doi: 10.1200/JCO.21.01755
   PubMed Web of Science ®Google Scholar
• Luznik L, Jalla S, Engstrom LW, et al. Durable engraftment of major histocompatibility complex–incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001 Dec 1;98(12):3456–3464. doi: 10.1182/blood.V98.12.3456
   PubMed Web of Science ®Google Scholar
• Luznik L, O’Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008 6;14(6):641–650. doi: 10.1016/j.bbmt.2008.03.005
   PubMed Web of Science ®Google Scholar
• Shaw BE, Jimenez-Jimenez AM, Burns LJ, et al. National Marrow donor program-sponsored multicenter, phase II trial of HLA-Mismatched unrelated donor bone Marrow transplantation using post-Transplant cyclophosphamide. J Clin Oncol. 2021 Jun 20;39(18):1971–1982. doi: 10.1200/JCO.20.03502
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Al Malki MM, Kongtim P, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation. Bone Marrow Transplant. 2020 Jan;55(1):12–24. doi: 10.1038/s41409-019-0499-z
   PubMed Web of Science ®Google Scholar
• Kasamon YL, Bolanos-Meade J, Prince GT, et al. Outcomes of nonmyeloablative HLA-Haploidentical Blood or Marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol. 2015 Oct 1;33(28):3152–3161. doi: 10.1200/JCO.2014.60.4777
   PubMed Web of Science ®Google Scholar
• Kasamon YL, Luznik L, Leffell MS, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant. 2010 Apr;16(4):482–489. doi: 10.1016/j.bbmt.2009.11.011
   PubMed Web of Science ®Google Scholar
• McCurdy SR, Kasamon YL, Kanakry CG, et al. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica. 2017 Feb;102(2):391–400. doi: 10.3324/haematol.2016.144139
   PubMed Web of Science ®Google Scholar
• Elmariah H, Kasamon YL, Zahurak M, et al. Haploidentical bone Marrow transplantation with post-Transplant cyclophosphamide using non–first-Degree related donors. Biol Blood Marrow Transplant. 2018 May;24(5):1099–1102. doi: 10.1016/j.bbmt.2018.02.005
   PubMed Web of Science ®Google Scholar
• Broers AEC, de Jong CN, Bakunina K, et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 2022 Jun 14;6(11):3378–3385. doi: 10.1182/bloodadvances.2021005847
   PubMed Web of Science ®Google Scholar
• Bolaños-Meade J, Reshef R, Fraser R, et al. Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematol. 2019 Mar;6(3):e132–e143. doi: 10.1016/S2352-3026(18)30221-7
   PubMed Web of Science ®Google Scholar
• Bolaños-Meade J, Hamadani M, Wu J, et al. Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis. N Engl J Med. 2023 Jun 22;388(25):2338–2348. doi: 10.1056/NEJMoa2215943
   PubMed Web of Science ®Google Scholar
• Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood. 1990 Oct 15;76(8):1464–1472. doi: 10.1182/blood.V76.8.1464.1464
   PubMed Web of Science ®Google Scholar
• Martin PJ, Rizzo JD, Wingard JR, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012 8;18(8):1150–1163. doi: 10.1016/j.bbmt.2012.04.005
   PubMed Web of Science ®Google Scholar
• Flowers MED, Martin PJ. How we treat chronic graft-versus-host disease. Blood. 2015 Jan 22;125(4):606–615. doi: 10.1182/blood-2014-08-551994
   PubMed Web of Science ®Google Scholar
• Lee SJ, Vogelsang G, Flowers MED. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003 4;9(4):215–233. doi: 10.1053/bbmt.2003.50026
   PubMed Web of Science ®Google Scholar
• Wolff D, Herzberg PY, Herrmann A, et al. Post-transplant multimorbidity index and quality of life in patients with chronic graft-versus-host disease-results from a joint evaluation of a prospective German multicenter validation trial and a cohort from the National Institutes of Health. Bone Marrow Transplant. 2021 Jan;56(1):243–256. doi: 10.1038/s41409-020-01017-8
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood. 1988 Aug;72(2):555–561. doi: 10.1182/blood.V72.2.555.555
   PubMed Web of Science ®Google Scholar
• Koc S, Leisenring W, Flowers MED, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002 Jul 1;100(1):48–51. doi: 10.1182/blood.V100.1.48
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood. 1981 2;57(2):267–276. doi: 10.1182/blood.V57.2.267.267
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988 8;72(2):546–554. doi: 10.1182/blood.V72.2.546.546
   PubMed Web of Science ®Google Scholar
• Drexler B, Buser A, Infanti L, et al. Extracorporeal photopheresis in graft-versus-host disease. Transfus Med Hemother. 2020 6;47(3):214–225. doi: 10.1159/000508169
   PubMed Web of Science ®Google Scholar
• Greinix HT, Ayuk F, Zeiser R. Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape. Leukemia. 2022 11;36(11):2558–2566. doi: 10.1038/s41375-022-01701-2
   PubMed Web of Science ®Google Scholar
• Greinix HT, van Besien K, Elmaagacli AH, et al. Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis–results of a crossover randomized study. Biol Blood Marrow Transplant. 2011 12;17(12):1775–1782. doi: 10.1016/j.bbmt.2011.05.004
   PubMed Web of Science ®Google Scholar
• Flowers MED, Apperley JF, van Besien K, et al. A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease. Blood. 2008 Oct 1;112(7):2667–2674. doi: 10.1182/blood-2008-03-141481
   PubMed Web of Science ®Google Scholar
• Greinix HT, Knobler RM, Worel N, et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica. 2006 3;91(3):405–408.
   PubMed Web of Science ®Google Scholar
• Greinix HT, Volc-Platzer B, Kalhs P, et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood. 2000 Oct 1;96(7):2426–2431. doi: 10.1182/blood.V96.7.2426
   PubMed Web of Science ®Google Scholar
• Greinix HT, Volc-Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood. 1998 Nov 1;92(9):3098–3104. doi: 10.1182/blood.V92.9.3098
   PubMed Web of Science ®Google Scholar
• Couriel DR, Hosing C, Saliba R, et al. Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. Blood. 2006 Apr 15;107(8):3074–3080. doi: 10.1182/blood-2005-09-3907
   PubMed Web of Science ®Google Scholar
• Krejci M, Doubek M, Buchler T, et al. Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease. Ann Hematol. 2005 10;84(10):681–685. doi: 10.1007/s00277-005-1070-0
   PubMed Web of Science ®Google Scholar
• Furlong T, Martin P, Flowers MED, et al. Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. Bone Marrow Transplant. 2009 12;44(11):739–748. doi: 10.1038/bmt.2009.76
   PubMed Web of Science ®Google Scholar
• Martin PJ, Storer BE, Rowley SD, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009 May 21;113(21):5074–5082. doi: 10.1182/blood-2009-02-202937
   PubMed Web of Science ®Google Scholar
• Sheskin J. THALIDOMIDE IN THE TREATMENT OF LEPRA REACTIONS. Clin Pharmacol Ther. 1965;6(3):303–306. doi: 10.1002/cpt196563303
   PubMed Web of Science ®Google Scholar
• Vogelsang GB, Farmer ER, Hess AD, et al. Thalidomide for the treatment of chronic graft-versus-host disease. N Engl J Med. 1992 Apr 16;326(16):1055–1058. doi: 10.1056/NEJM199204163261604
   PubMed Web of Science ®Google Scholar
• Arora M, Wagner JE, Davies SM, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2001;7(5):265–273. doi: 10.1053/bbmt.2001.v7.pm11400948
   PubMed Web of Science ®Google Scholar
• Antin JH, Kim HT, Cutler C, et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood. 2003 Sep 1;102(5):1601–1605. doi: 10.1182/blood-2003-02-0489
   PubMed Web of Science ®Google Scholar
• Cutler C, Antin JH. Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transplant. 2004 9;34(6):471–476. doi: 10.1038/sj.bmt.1704604
   PubMed Web of Science ®Google Scholar
• Cutler C, Kim HT, Hochberg E, et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2004 5;10(5):328–336. doi: 10.1016/j.bbmt.2003.12.305
   PubMed Web of Science ®Google Scholar
• Shegogue D, Trojanowska M. Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway. J Biol Chem. 2004 May 28;279(22):23166–23175. doi: 10.1074/jbc.M401238200
   PubMed Web of Science ®Google Scholar
• Carpenter PA, Logan BR, Lee SJ, et al. A phase II/III randomized, multicenter trial of prednisone/sirolimus prednisone/sirolimus/calcineurin inhibitor for the treatment of chronic graft–host disease: BMT CTN 0801. Haematologica. 2018 Nov;103(11):1915–1924. doi: 10.3324/haematol.2018.195123
   PubMed Web of Science ®Google Scholar
• Zaja F, Bacigalupo A, Patriarca F, et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant. 2007 Aug;40(3):273–277. doi: 10.1038/sj.bmt.1705725
   PubMed Web of Science ®Google Scholar
• Canninga-van Dijk MR, van der Straaten HM, Fijnheer R, et al. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease. Blood. 2004 Oct 15;104(8):2603–2606. doi: 10.1182/blood-2004-05-1855
   PubMed Web of Science ®Google Scholar
• Okamoto M, Okano A, Akamatsu S, et al. Rituximab is effective for steroid-refractory sclerodermatous chronic graft-versus-host disease. Leukemia. 2006 Jan;20(1):172–173. doi: 10.1038/sj.leu.2403996
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Carson E, Reynolds C, et al. Anti-CD20 chimeric monoclonal antibody treatment of refractory immune-mediated thrombocytopenia in a patient with chronic graft-versus-host disease. Ann Intern Med. 2000 Aug 15;133(4):275–279. doi: 10.7326/0003-4819-133-4-200008150-00011
   PubMed Web of Science ®Google Scholar
• Ratanatharathorn V, Ayash L, Reynolds C, et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003 Aug;9(8):505–511. doi: 10.1016/S1083-8791(03)00216-7
   PubMed Web of Science ®Google Scholar
• Cutler C, Miklos D, Kim HT, et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood. 2006 Jul 15;108(2):756–762. doi: 10.1182/blood-2006-01-0233
   PubMed Web of Science ®Google Scholar
• Kim SJ, Lee JW, Jung CW, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica. 2010 Nov;95(11):1935–1942. doi: 10.3324/haematol.2010.026104
   PubMed Web of Science ®Google Scholar
• Jeon Y, Lim J-Y, Im K-I, et al. BAFF blockade attenuates acute graft-versus-host disease directly the dual regulation of T- and B-cell homeostasis. Front Immunol. 2022 Dec 6;13:995149. doi: 10.3389/fimmu.2022.995149
   PubMed Web of Science ®Google Scholar
• Barmettler S, Ong M-S, Farmer JR, et al. Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open. 2018 Nov 2;1(7):e184169. doi: 10.1001/jamanetworkopen.2018.4169
   PubMed Web of Science ®Google Scholar
• Lucas F, Woyach JA. Inhibiting Bruton’s tyrosine kinase in CLL and other B-Cell malignancies. Targ Oncol. 2019 4;14(2):125–138. doi: 10.1007/s11523-019-00635-7
   PubMed Web of Science ®Google Scholar
• da Cunha-Bang C, Niemann CU. Targeting Bruton’s Tyrosine Kinase across B-cell malignancies. Drugs. 2018 11;78(16):1653–1663. doi: 10.1007/s40265-018-1003-6
   PubMed Web of Science ®Google Scholar
• Palaniyandi S, Strattan E, Kumari R, et al. Combinatorial inhibition of tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease. Bone Marrow Transplant. 2023 May 9;58(8):924–935. doi: 10.1038/s41409-023-02001-8
   PubMed Web of Science ®Google Scholar
• Miklos DB, Abu Zaid M, Cooney JP, et al. Ibrutinib for first-line treatment of chronic graft-versus-host disease: results from the randomized phase III iNTEGRATE Study. J Clin Oncol. 2023 Apr 1;41(10):1876–1887. doi: 10.1200/JCO.22.00509
   PubMed Web of Science ®Google Scholar
• Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017 Nov 23;130(21):2243–2250. doi: 10.1182/blood-2017-07-793786
   PubMed Web of Science ®Google Scholar
• Waller EK, Miklos D, Cutler C, et al.Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b/2 study. Biol Blood Marrow Transplant. 2019 10;25(10): 2002–2007. 10.1016/j.bbmt.2019.06.023
   PubMed Web of Science ®Google Scholar
• Chin KK, Kim HT, Inyang EA, et al. Ibrutinib in steroid-refractory chronic graft-versus-host disease, a single-center experience. Transplant Cell Ther. 2021 Dec;27(12):e990 1–e990 7. doi: 10.1016/j.jtct.2021.08.017
   Google Scholar
• Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015 Oct;29(10):2062–2068. doi: 10.1038/leu.2015.212
   PubMed Web of Science ®Google Scholar
• Zeiser R, von Bubnoff N, Butler J, et al. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease. N Engl J Med. 2020 May 7;382(19):1800–1810. doi: 10.1056/NEJMoa1917635
   PubMed Web of Science ®Google Scholar
• White J, Elemary M, Linn SM, et al. A multicenter, retrospective study evaluating clinical outcomes of ruxolitinib therapy in heavily pretreated chronic GVHD patients with steroid failure. Transplant Cell Ther. 2023 Feb;29(2):.e120.1–.e120.9. doi: 10.1016/j.jtct.2022.11.025
   Google Scholar
• Zeiser R, Polverelli N, Ram R, et al. Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease. N Engl J Med. 2021 Jul 15;385(3):228–238. doi: 10.1056/NEJMoa2033122
   PubMed Web of Science ®Google Scholar
• Zanin-Zhorov A, Weiss JM, Nyuydzefe MS, et al. Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16814–16819. doi: 10.1073/pnas.1414189111
   PubMed Web of Science ®Google Scholar
• Flynn R, Paz K, Du J, et al. Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood. 2016 Apr 28;127(17):2144–2154. doi: 10.1182/blood-2015-10-678706
   PubMed Web of Science ®Google Scholar
• Jagasia M, Lazaryan A, Bachier CR, et al. ROCK2 inhibition with belumosudil (KD025) for the treatment of chronic graft-versus-host disease. J Clin Oncol. 2021 Jun 10;39(17):1888–1898. doi: 10.1200/JCO.20.02754
   PubMed Web of Science ®Google Scholar
• Przepiorka D, Le RQ, Ionan A, et al. FDA approval summary: belumosudil for adult and pediatric patients 12 years and older with chronic GvHD after two or more prior lines of systemic therapy. Clin Cancer Res. 2022 Jun 13;28(12):2488–2492. doi: 10.1158/1078-0432.CCR-21-4176
   PubMed Web of Science ®Google Scholar
• Cutler C, Lee SJ, Arai S, et al. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar study. Blood. 2021 Dec 2;138(22):2278–2289. doi: 10.1182/blood.2021012021
   PubMed Web of Science ®Google Scholar
• Alexander KA, Flynn R, Lineburg KE, et al. CSF-1–dependant donor-derived macrophages mediate chronic graft-versus-host disease. J Clin Invest. 2014 Oct;124(10):4266–4280. doi: 10.1172/JCI75935
   PubMed Web of Science ®Google Scholar
• Kitko CL, Arora M, DeFilipp Z, et al. Axatilimab for chronic graft-versus-host disease after failure of at least two prior systemic therapies: results of a phase I/II study. J Clin Oncol. 2023 Apr 1;41(10):1864–1875. doi: 10.1200/JCO.22.00958
   PubMed Web of Science ®Google Scholar
• Lee SJ, Arora M, Defilipp Z, et al. Safety, tolerability, and efficacy of axatilimab, a CSF-1R humanized antibody, for chronic graft-versus-host disease after 2 or more lines of systemic treatment. Blood. 2021 Nov 5;138(Supplement 1):263–263. doi: 10.1182/blood-2021-146050
   Google Scholar
• A study of axatilimab at 3 different doses in participants with chronic graft versus host disease (cGVHD). [Accessed 2023 August 1]. https://classic.clinicaltrials.gov/ct2/show/NCT04710576
   Google Scholar
• Yu C-C, Fornoni A, Weins A, et al. Abatacept in B7-1–Positive Proteinuric Kidney Disease. N Engl J Med. 2013 Dec 19;369(25):2416–2423. doi: 10.1056/NEJMoa1304572
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker J-C, Schiff M, et al. Abatacept for Rheumatoid Arthritis refractory to tumor necrosis factor α inhibition. N Engl J Med. 2005 Sep 15;353(11):1114–1123. doi: 10.1056/NEJMoa050524
   PubMed Web of Science ®Google Scholar
• Via CS, Rus V, Nguyen P, et al. Differential effect of CTLA4Ig on murine Graft-Versus-Host Disease (GVHD) development: CTLA4Ig prevents both acute and chronic GVHD development but reverses only chronic GVHD. J Immunol. 1996 Nov 1;157(9):4258–4267. doi: 10.4049/jimmunol.157.9.4258
   PubMed Web of Science ®Google Scholar
• Nahas MR, Soiffer RJ, Kim HT, et al. Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 2018 Jun 21;131(25):2836–2845. doi: 10.1182/blood-2017-05-780239
   PubMed Web of Science ®Google Scholar
• Koshy AG, Kim HT, Liegel J, et al. Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. Blood. 2023 Jun 15;141(24):2932–2943. doi: 10.1182/blood.2022019107
   PubMed Web of Science ®Google Scholar
• Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012 Feb 17;12(3):180–190.
   PubMed Web of Science ®Google Scholar
• Chinen T, Kannan AK, Levine AG, et al. An essential role for the IL-2 receptor in T cell function. Nat Immunol. 2016 Nov;17(11):1322–1333. doi: 10.1038/ni.3540
   PubMed Web of Science ®Google Scholar
• Malek TR, Bayer AL. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol. 2004 Sep;4(9):665–674. doi: 10.1038/nri1435
   PubMed Web of Science ®Google Scholar
• Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol. 2004 Apr 1;172(7):3983–3988.
   PubMed Web of Science ®Google Scholar
• Overwijk WW, Tagliaferri MA, Zalevsky J. Engineering IL-2 to give new life to T cell immunotherapy. Annu Rev Med. 2021 Jan 27;72(1):281–311.
   PubMedGoogle Scholar
• Matsuoka K-I, Kim HT, McDonough S, et al. Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2010 May;120(5):1479–1493. doi: 10.1172/JCI41072
   PubMed Web of Science ®Google Scholar
• Buckner JH. Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases. Nat Rev Immunol. 2010 Dec;10(12):849–859. doi: 10.1038/nri2889
   PubMed Web of Science ®Google Scholar
• Koreth J, Antin JH. Current and future approaches for control of graft-versus-host disease. Expert Rev Hematol. 2008 Oct;1(1):111. doi: 10.1586/17474086.1.1.111
   PubMed Web of Science ®Google Scholar
• Koreth J, Matsuoka K-I, Kim HT, et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med. 2011 Dec 1;365(22):2055–2066. doi: 10.1056/NEJMoa1108188
   PubMed Web of Science ®Google Scholar
• Matsuoka K-I, Koreth J, Kim HT, et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med. 2013 Apr 3;5(179):179ra43. doi: 10.1126/scitranslmed.3005265
   PubMed Web of Science ®Google Scholar
• Mo X-D, Zhang X-H, Xu L-P, et al. Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2017 May;96(5):829–838. doi: 10.1007/s00277-017-2960-7
   PubMed Web of Science ®Google Scholar
• Ogasawara M, Nozu R, Miki K, et al. Donor lymphocyte infusion for relapsed acute leukemia or myelodysplastic syndrome after hematopoietic stem cell transplantation: a single-Institute retrospective analysis. Intern Med. 2023 May 24. doi: 10.2169/internalmedicine.1714-23
   Google Scholar
• Ho VT, Kim HT, Kao G, et al. Sequential infusion of donor-derived dendritic cells with donor lymphocyte infusion for relapsed hematologic cancers after allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2014 Dec;89(12):1092–1096. doi: 10.1002/ajh.23825
   PubMed Web of Science ®Google Scholar
• Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party. J Clin Oncol. 2007 Nov 1;25(31):4938–4945. doi: 10.1200/JCO.2007.11.6053
   PubMed Web of Science ®Google Scholar
• Oba U, Koga Y, Suminoe A, et al. Donor lymphocyte infusion is an effective therapy for relapsed Hodgkin lymphoma after reduced-intensity allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2014 Nov;100(5):511–513. doi: 10.1007/s12185-014-1654-3
   PubMed Web of Science ®Google Scholar
• Rager A, Porter DL. Cellular therapy following allogeneic stem-cell transplantation. Ther Adv Hematol. 2011 Dec;2(6):409–428. doi: 10.1177/2040620711412416
   PubMedGoogle Scholar
• Soiffer RJ. Donor lymphocyte infusions for acute myeloid leukaemia. Best Pract Res Clin Haematol. 2008 Sep;21(3):455–466. doi: 10.1016/j.beha.2008.07.009
   PubMed Web of Science ®Google Scholar
• Soiffer RJ, Alyea EP, Hochberg E, et al. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant. 2002;8(11):625–632. doi: 10.1053/bbmt.2002.v8.abbmt080625
   PubMed Web of Science ®Google Scholar
• Porter DL, Antin JH. Donor leukocyte infusions in myeloid malignancies: new strategies. Best Pract Res Clin Haematol. 2006;19(4):737–755. doi: 10.1016/j.beha.2006.05.003
   PubMed Web of Science ®Google Scholar
• Matte CC, Cormier J, Anderson BE, et al. Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing. Blood. 2004 Jun 1;103(11):4353–4361. doi: 10.1182/blood-2003-10-3735
   PubMed Web of Science ®Google Scholar
• Bachireddy P, Azizi E, Burdziak C, et al. Mapping the evolution of T cell states during response and resistance to adoptive cellular therapy. Cell Rep. 2021 Nov 9;37(6):109992. doi: 10.1016/j.celrep.2021.109992
   PubMed Web of Science ®Google Scholar
• Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone Marrow Transplant. Blood. 1998 May 15;91(10):3671–3680. doi: 10.1182/blood.V91.10.3671
   PubMed Web of Science ®Google Scholar
• Symons HJ, Levy MY, Wang J, et al. The allogeneic effect revisited: exogenous help for endogenous, tumor-specific T cells. Biol Blood Marrow Transplant. 2008 May;14(5):499–509. doi: 10.1016/j.bbmt.2008.02.013
   PubMed Web of Science ®Google Scholar
• Chakraverty R, Eom H-S, Sachs J, et al. Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions. Blood. 2006 Sep 15;108(6):2106–2113. doi: 10.1182/blood-2006-03-007427
   PubMed Web of Science ®Google Scholar
• Rezvani K, Barrett AJ. Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation. Best Pract Res Clin Haematol. 2008 Sep;21(3):437–453. doi: 10.1016/j.beha.2008.07.004
   PubMed Web of Science ®Google Scholar
• Wilm B, Muñoz-Chapuli R. The role of WT1 in embryonic development and normal organ homeostasis. Methods Mol Biol. 2016;1467:23–39.
   PubMedGoogle Scholar
• Oka Y, Elisseeva OA, Tsuboi A, et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms’ tumor gene (WT1) product. Immunogenetics. 2000 Feb;51(2):99–107. doi: 10.1007/s002510050018
   PubMed Web of Science ®Google Scholar
• Gao L, Bellantuono I, Elsässer A, et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood. 2000 Apr 1;95(7):2198–2203. doi: 10.1182/blood.V95.7.2198
   PubMed Web of Science ®Google Scholar
• Chapuis AG, Ragnarsson GB, Nguyen HN, et al. Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med. 2013 Feb 27;5(174):174ra27. doi: 10.1126/scitranslmed.3004916
   PubMed Web of Science ®Google Scholar
• Tawara I, Kageyama S, Miyahara Y, et al. Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS. Blood. 2017 Nov 2;130(18):1985–1994. doi: 10.1182/blood-2017-06-791202
   PubMed Web of Science ®Google Scholar
• Chapuis AG, Egan DN, Bar M, et al. T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant. Nat Med. 2019 Jul;25(7):1064–1072. doi: 10.1038/s41591-019-0472-9
   PubMed Web of Science ®Google Scholar
• Van Tendeloo VF, Van de Velde A, Van Driessche A, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13824–13829. doi: 10.1073/pnas.1008051107
   PubMed Web of Science ®Google Scholar
• Anguille S, Van de Velde AL, Smits EL, et al. Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. Blood. 2017 Oct 12;130(15):1713–1721. doi: 10.1182/blood-2017-04-780155
   PubMed Web of Science ®Google Scholar
• Di Stasi A, Jimenez AM, Minagawa K, et al. Review of the results of WT1 peptide vaccination strategies for myelodysplastic syndromes and acute myeloid leukemia from nine different studies. Front Immunol. 2015 Feb 4;6:36.
   PubMed Web of Science ®Google Scholar
• Akahori Y, Wang L, Yoneyama M, et al. Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination. Blood. 2018 Sep 13;132(11):1134–1145. doi: 10.1182/blood-2017-08-802926
   PubMed Web of Science ®Google Scholar
• Dao T, Pankov D, Scott A, et al. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nat Biotechnol. 2015 Oct;33(10):1079–1086. doi: 10.1038/nbt.3349
   PubMed Web of Science ®Google Scholar
• Augsberger C, Hänel G, Xu W, et al. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody. Blood. 2021 Dec 23;138(25):2655–2669. doi: 10.1182/blood.2020010477
   PubMed Web of Science ®Google Scholar
• Ruggiero E, Carnevale E, Prodeus A, et al. CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function. Sci Transl Med. 2022 Feb 9;14(631):eabg8027. doi: 10.1126/scitranslmed.abg8027
   PubMed Web of Science ®Google Scholar
• Ishikawa T, Fujii N, Imada M, et al. Graft-versus-leukemia effect with a WT1-specific T-cell response induced by azacitidine and donor lymphocyte infusions after allogeneic hematopoietic stem cell transplantation. Cytotherapy. 2017 Apr;19(4):514–520. doi: 10.1016/j.jcyt.2016.12.007
   PubMed Web of Science ®Google Scholar
• Naik S, Vasileiou S, Tzannou I, et al. Donor-derived multiple leukemia antigen–specific T-cell therapy to prevent relapse after transplant in patients with ALL. Blood. 2022 Apr 28;139(17):2706–2711. doi: 10.1182/blood.2021014648
   PubMed Web of Science ®Google Scholar
• Steger B, Floro L, Amberger DC, et al. WT1, PRAME, and PR3 mRNA Expression in Acute Myeloid Leukemia (AML). J Immunother. 2020;43(6):204–215. doi: 10.1097/CJI.0000000000000322
   PubMed Web of Science ®Google Scholar
• Huang Q-S, Wang J-Z, Qin Y-Z, et al. Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia. Blood Adv. 2019 Nov 12;3(21):3406–3418. doi: 10.1182/bloodadvances.2019000564
   PubMed Web of Science ®Google Scholar
• McLarnon A, Piper KP, Goodyear OC, et al. CD8+ T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect. Haematologica. 2010 Sep;95(9):1572–1578. doi: 10.3324/haematol.2009.019539
   PubMed Web of Science ®Google Scholar
• Xue L, Hu Y, Wang J, et al. T cells targeting multiple tumor-associated antigens as a postremission treatment to prevent or delay relapse in acute myeloid leukemia. Cancer Manag Res. 2019 Jul 16;11:6467–6476.
   PubMed Web of Science ®Google Scholar
• Kinoshita H, Cooke KR, Grant M, et al. Outcome of donor-derived TAA-T cell therapy in patients with high-risk or relapsed acute leukemia post allogeneic BMT. Blood Adv. 2022 Apr 26;6(8):2520–2534. doi: 10.1182/bloodadvances.2021006831
   PubMed Web of Science ®Google Scholar
• Lulla PD, Naik S, Vasileiou S, et al. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant. Blood. 2021 May 13;137(19):2585–2597. doi: 10.1182/blood.2020009471
   PubMed Web of Science ®Google Scholar
• Biernacki MA, Sheth VS, Bleakley M. T cell optimization for graft-versus-leukemia responses. JCI Insight. 2020 May 7;5(9). doi: 10.1172/jci.insight.134939
   PubMed Web of Science ®Google Scholar
• Riddell SR, Bleakley M, Nishida T, et al. Adoptive transfer of allogeneic antigen-specific T cells. Biol Blood Marrow Transplant. 2006 Jan;12(1 Suppl 1):9–12. doi: 10.1016/j.bbmt.2005.10.025
   PubMed Web of Science ®Google Scholar
• Anderson LD Jr., Mori S, Mann S, et al. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease. Cancer Res. 2000 Oct 15;60(20):5797–5802.
   PubMed Web of Science ®Google Scholar
• Anderson LD Jr., Savary CA, Mullen CA. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. Blood. 2000 Apr 1;95(7):2426–2433.
   PubMed Web of Science ®Google Scholar
• Warren EH, Zhang XC, Li S, et al. Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT. Blood. 2012 Oct 4;120(14):2796–2806. doi: 10.1182/blood-2012-04-347286
   PubMed Web of Science ®Google Scholar
• Spierings E, Kim Y-H, Hendriks M, et al. Multicenter analyses demonstrate significant clinical effects of minor histocompatibility antigens on GvHD and GvL after HLA-matched related and unrelated hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Aug;19(8):1244–1253. doi: 10.1016/j.bbmt.2013.06.001
   PubMed Web of Science ®Google Scholar
• Bleakley M, Riddell SR. Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia. Immunol Cell Biol. 2011 Mar;89(3):396–407. doi: 10.1038/icb.2010.124
   PubMed Web of Science ®Google Scholar
• Fleischhauer K, Beelen DW. HLA mismatching as a strategy to reduce relapse after alternative donor transplantation. Semin Hematol. 2016 Apr;53(2):57–64. doi: 10.1053/j.seminhematol.2016.01.010
   PubMed Web of Science ®Google Scholar
• Griffioen M, van Bergen CAM, Falkenburg JHF. Autosomal Minor Histocompatibility Antigens: How Genetic Variants Create Diversity in Immune Targets. Front Immunol. 2016 Mar 15;7:100. doi: 10.3389/fimmu.2016.00100
   PubMed Web of Science ®Google Scholar
• Cieri N, Hookeri N, Stromhaug K, et al. Systematic Identification of autosomal and Y-Encoded minor histocompatibility antigens reveals predictors of chronic gvhd and candidate GVL targets. Blood. 2022 Nov 15;140(Supplement 1):4762–4764. doi: 10.1182/blood-2022-162841
   Google Scholar
• DeLuca DS, Eiz-Vesper B, Ladas N, et al. High-throughput minor histocompatibility antigen prediction. Bioinformatics. 2009 Sep 15;25(18):2411–2417. doi: 10.1093/bioinformatics/btp404
   PubMed Web of Science ®Google Scholar
• Lansford JL, Dharmasiri U, Chai S, et al. Computational modeling and confirmation of leukemia-associated minor histocompatibility antigens. Blood Adv. 2018 Aug 28;2(16):2052–2062. doi: 10.1182/bloodadvances.2018022475
   PubMed Web of Science ®Google Scholar
• Olsen KS, Jadi O, Dexheimer S, et al. Shared graft-versus-leukemia minor histocompatibility antigens in DISCOVeRY-BMT. Blood Adv. 2023 May 9;7(9):1635–1649. doi: 10.1182/bloodadvances.2022008863
   PubMed Web of Science ®Google Scholar
• Hombrink P, Hassan C, Kester MGD, et al. Identification of biological relevant minor histocompatibility antigens within the B-lymphocyte-derived HLA-Ligandome using a reverse immunology approach. Clin Cancer Res. 2015 May 1;21(9):2177–2186. doi: 10.1158/1078-0432.CCR-14-2188
   PubMed Web of Science ®Google Scholar
• Armistead PM, Liang S, Li H, et al. Common minor histocompatibility antigen discovery based upon patient clinical outcomes and genomic data. PLoS One. 2011 Aug 9;6(8):e23217. doi: 10.1371/journal.pone.0023217
   PubMed Web of Science ®Google Scholar
• Li N, Matte-Martone C, Zheng H, et al. Memory T cells from minor histocompatibility antigen–vaccinated and virus-immune donors improve GVL and immune reconstitution. Blood. 2011 Nov 24;118(22):5965–5976. doi: 10.1182/blood-2011-07-367011
   PubMed Web of Science ®Google Scholar
• Summers C, Sheth VS, Bleakley M. Minor Histocompatibility Antigen-Specific T Cells. Front Pediatr. 2020 Jun 3;8:284. doi: 10.3389/fped.2020.00284
   PubMed Web of Science ®Google Scholar
• Bund D, Buhmann R, Gökmen F, et al. Minor histocompatibility antigen UTY as target for graft-versus-leukemia and graft-versus-haematopoiesis in the canine model. Scand J Immunol. 2013 Jan;77(1):39–53. doi: 10.1111/sji.12011
   PubMed Web of Science ®Google Scholar
• van Bergen CAM, van Luxemburg-Heijs SAP, de Wreede LC, et al. Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response. J Clin Invest. 2017 Feb 1;127(2):517–529. doi: 10.1172/JCI86175
   PubMed Web of Science ®Google Scholar
• van der Zouwen B, Kruisselbrink AB, Frederik Falkenburg JH, et al. Collateral damage of nonhematopoietic tissue by hematopoiesis-specific T cells results in graft-versus-host disease during an ongoing profound graft-versus-leukemia reaction. Biol Blood Marrow Transplant. 2014 Jun;20(6):760–769. doi: 10.1016/j.bbmt.2014.03.002
   PubMed Web of Science ®Google Scholar
• Laurin D, Hannani D, Pernollet M, et al. Immunomonitoring of graft-versus-host minor histocompatibility antigen correlates with graft-versus-host disease and absence of relapse after graft. Transfusion. 2010 Feb;50(2):418–428. doi: 10.1111/j.1537-2995.2009.02440.x
   PubMed Web of Science ®Google Scholar
• Stumpf AN, van der Meijden ED, van Bergen CAM, et al. Identification of 4 new HLA-DR–restricted minor histocompatibility antigens as hematopoietic targets in antitumor immunity. Blood. 2009 Oct 22;114(17):3684–3692. doi: 10.1182/blood-2009-03-208017
   PubMed Web of Science ®Google Scholar
• Nakamura R, La Rosa C, Tsai W, et al. Ex vivo detection of CD8 T cells specific for H-Y minor histocompatibility antigens in allogeneic hematopoietic stem cell transplant recipients. Transpl Immunol. 2014 May;30(4):128–135. doi: 10.1016/j.trim.2014.02.001
   PubMed Web of Science ®Google Scholar
• Fuji S, Kapp M, Einsele H. Alloreactivity of virus-specific T cells: possible implication of graft-versus-host disease and graft-versus-leukemia effects. Front Immunol. 2013 Oct 14;4:330. doi: 10.3389/fimmu.2013.00330
   PubMed Web of Science ®Google Scholar
• Heemskerk MHM, Hoogeboom M, Hagedoorn R, et al. Reprogramming of virus-specific T cells into leukemia-reactive T cells using T cell receptor gene transfer. J Exp Med. 2004 Apr 5;199(7):885–894. doi: 10.1084/jem.20031110
   PubMed Web of Science ®Google Scholar
• Koldehoff M, Lindemann M, Opalka B, et al. Cytomegalovirus induces apoptosis in acute leukemia cells as a virus-versus-leukemia function. Leuk Lymphoma. 2015 May 15;56(11):3189–3197. doi: 10.3109/10428194.2015.1032968
   PubMed Web of Science ®Google Scholar
• van Balen P, Jedema I, van Loenen MM, et al. HA-1H T-Cell receptor gene transfer to redirect virus-specific T cells for treatment of hematological malignancies after allogeneic stem cell transplantation: a phase 1 clinical study. Front Immunol. 2020 Aug 20;11:1804.
   PubMed Web of Science ®Google Scholar
• Ho VT, Kim HT, Brock J, et al. GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. Blood Adv. 2022 Apr 12;6(7):2183–2194. doi: 10.1182/bloodadvances.2021006255
   PubMed Web of Science ®Google Scholar
• Rosenblatt J, Stone RM, Uhl L, et al. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. Sci Transl Med. 2016 Dec 7;8(368):368ra171. doi: 10.1126/scitranslmed.aag1298
   PubMed Web of Science ®Google Scholar
• Zhou M, Sacirbegovic F, Zhao K, et al. T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect. Nat Commun. 2020 Aug 24;11(1):4227. doi: 10.1038/s41467-020-17991-y
   PubMed Web of Science ®Google Scholar
• Koestner W, Hapke M, Herbst J, et al. PD-L1 blockade effectively restores strong graft-versus-leukemia effects without graft-versus-host disease after delayed adoptive transfer of T-cell receptor gene-engineered allogeneic CD8+ T cells. Blood. 2011 Jan 20;117(3):1030–1041. doi: 10.1182/blood-2010-04-283119
   PubMed Web of Science ®Google Scholar
• Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for Patients with Relapse after Allogeneic Transplantation. N Engl J Med. 2016 Jul 14;375(2):143–153. doi: 10.1056/NEJMoa1601202
   PubMed Web of Science ®Google Scholar
• Penter L, Zhang Y, Savell A, et al. Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation. Blood. 2021 Jun 10;137(23):3212–3217. doi: 10.1182/blood.2021010867
   PubMed Web of Science ®Google Scholar
• Gournay V, Vallet N, Peux V, et al. Immune landscape after allo-HSCT: TIGIT- and CD161-expressing CD4 T cells are associated with subsequent leukemia relapse. Blood. 2022 Sep 15;140(11):1305–1321. doi: 10.1182/blood.2022015522
   PubMed Web of Science ®Google Scholar
• Minnie SA, Waltner OG, Ensbey KS, et al. Depletion of exhausted alloreactive T cells enables targeting of stem-like memory T cells to generate tumor-specific immunity. Sci Immunol. 2022 Oct 21;7(76):eabo3420. doi: 10.1126/sciimmunol.abo3420
   PubMed Web of Science ®Google Scholar
• Yao S, Jianlin C, Zhuoqing Q, et al. Case report: combination therapy with PD-1 blockade for acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation resulted in fatal GVHD. Front Immunol. 2021 Apr 1;12:639217.
   PubMedGoogle Scholar
• Teshima T, Hill GR, Pan L, et al. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation. J Clin Invest. 1999 Aug;104(3):317–325. doi: 10.1172/JCI7111
   PubMed Web of Science ®Google Scholar
• Yang Y-G, Sergio JJ, Pearson DA, et al. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice. Blood. 1997 Dec 1;90(11):4651–4660. doi: 10.1182/blood.V90.11.4651
   PubMed Web of Science ®Google Scholar
• Reddy V, Winer AG, Eksioglu E, et al. Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 Dec;11(12):1014–1021. doi: 10.1016/j.bbmt.2005.08.032
   PubMed Web of Science ®Google Scholar
• Sykes M, Abraham VS, Harty MW, et al. IL-2 reduces graft-versus-host disease and preserves a graft-versus-leukemia effect by selectively inhibiting CD4+ T cell activity. J Immunol. 1993 Jan 1;150(1):197–205. doi: 10.4049/jimmunol.150.1.197
   PubMed Web of Science ®Google Scholar
• Darlak KA, Wang Y, Li J-M, et al. Enrichment of IL-12–producing plasmacytoid dendritic cells in donor bone Marrow grafts enhances graft-versus-leukemia activity in allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Sep;19(9):1331–1339. doi: 10.1016/j.bbmt.2013.06.016
   PubMed Web of Science ®Google Scholar
• Reddy P, Teshima T, Hildebrandt G, et al. Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation. Blood. 2002 Nov 1;100(9):3429–3431. doi: 10.1182/blood-2002-04-1252
   PubMed Web of Science ®Google Scholar
• Reddy P, Teshima T, Hildebrandt G, et al. Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects. Blood. 2003 Apr 1;101(7):2877–2885. doi: 10.1182/blood-2002-08-2566
   PubMed Web of Science ®Google Scholar
• Burchert A, Bug G, Fritz LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with -internal tandem duplication mutation (SORMAIN). J Clin Oncol. 2020 Sep 10;38(26):2993–3002. doi: 10.1200/JCO.19.03345
   PubMed Web of Science ®Google Scholar
• Mathew NR, Baumgartner F, Braun L, et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018 Mar;24(3):282–291. doi: 10.1038/nm.4484
   PubMed Web of Science ®Google Scholar
• Romee R, Cooley S, Berrien-Elliott MM, et al. First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood. 2018 Jun 7;131(23):2515–2527. doi: 10.1182/blood-2017-12-823757
   PubMed Web of Science ®Google Scholar
• Yang Y-G, Wang H, Asavaroengchai W, et al. Role of interferon-gamma in GVHD and GVL. Cell Mol Immunol. 2005 Oct;2(5):323–329.
   PubMed Web of Science ®Google Scholar
• Wang H, Yang Y-G. The complex and central role of interferon-γ in graft-versus-host disease and graft-versus-tumor activity. Immunol Rev. 2014 Mar;258(1):30–44. doi: 10.1111/imr.12151
   PubMed Web of Science ®Google Scholar
• Matte-Martone C, Liu J, Zhou M, et al. Differential requirements for myeloid leukemia IFN-γ conditioning determine graft-versus-leukemia resistance and sensitivity. J Clin Invest. 2017 Jun 30;127(7):2765–2776. doi: 10.1172/JCI85736
   PubMed Web of Science ®Google Scholar
• Klauer LK, Schutti O, Ugur S, et al. Interferon gamma secretion of adaptive and innate immune cells as a parameter to describe leukaemia-derived dendritic-cell-mediated immune responses in acute myeloid leukaemia in vitro. Transfus Med Hemother. 2022 Feb;49(1):44–61. doi: 10.1159/000516886
   PubMed Web of Science ®Google Scholar
• Robb RJ, Kreijveld E, Kuns RD, et al. Type I-IFNs control GVHD and GVL responses after transplantation. Blood. 2011 Sep 22;118(12):3399–3409. doi: 10.1182/blood-2010-12-325746
   PubMed Web of Science ®Google Scholar
• Ito S, Krakow EF, Ventura K, et al. Pilot trial of IFN-γ and donor lymphocyte infusion to treat relapsed AML and MDS after allogeneic hematopoietic stem cell transplantation. Blood. 2022 Nov 15;140(Supplement 1):7678–7679. doi: 10.1182/blood-2022-157054
   Google Scholar
• Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol. 2008 Apr 18;9(5):503–510. doi: 10.1038/ni1582
   PubMed Web of Science ®Google Scholar
• Braud VM, Allan DS, O’Callaghan CA, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature. 1998 Feb 19;391(6669):795–799. doi: 10.1038/35869
   PubMed Web of Science ®Google Scholar
• Lee N, Llano M, Carretero M, et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5199–5204. doi: 10.1073/pnas.95.9.5199
   PubMed Web of Science ®Google Scholar
• Shifrin N, Raulet DH, Ardolino M. NK cell self tolerance, responsiveness and missing self recognition. Semin Immunol. 2014 Apr;26(2):138–144. doi: 10.1016/j.smim.2014.02.007
   PubMed Web of Science ®Google Scholar
• Pende D, Falco M, Vitale M, et al. Killer ig-like receptors (KIRs): their role in NK cell modulation and developments leading to their clinical exploitation. Front Immunol. 2019 May 28;10:1179.
   PubMed Web of Science ®Google Scholar
• Ciccone E, Viale O, Pende D, et al. Specific lysis of allogeneic cells after activation of CD3- lymphocytes in mixed lymphocyte culture. J Exp Med. 1988 Dec 1;168(6):2403–2408. doi: 10.1084/jem.168.6.2403
   PubMed Web of Science ®Google Scholar
• Vivier E, Colonna M. Immunobiology of natural killer cell receptors. Heidelberg: Springer Science & Business Media; 2005 Dec 20.
   Google Scholar
• Ciccone E, Colonna M, Viale O, et al. Susceptibility or resistance to lysis by alloreactive natural killer cells is governed by a gene in the human major histocompatibility complex between BF and HLA-B. Proc Natl Acad Sci U S A. 1990 Dec;87(24):9794–9797. doi: 10.1073/pnas.87.24.9794
   PubMed Web of Science ®Google Scholar
• Colonna M, Spies T, Strominger JL, et al. Alloantigen recognition by two human natural killer cell clones is associated with HLA-C or a closely linked gene. Proc Natl Acad Sci U S A. 1992 Sep 1;89(17):7983–7985. doi: 10.1073/pnas.89.17.7983
   PubMed Web of Science ®Google Scholar
• Colonna M, Brooks EG, Falco M, et al. Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science. 1993 May 21;260(5111):1121–1124. doi: 10.1126/science.8493555
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Mancusi A, et al. Natural killer cell alloreactivity in haploidentical hematopoietic stem cell transplantation. Int J Hematol. 2005 Jan;81(1):13–17. doi: 10.1532/IJH97.04172
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-Mismatched hematopoietic stem cell transplantation. Blood. 1999 Jul 1;94(1):333–339. doi: 10.1182/blood.V94.1.333.413a31_333_339
   PubMed Web of Science ®Google Scholar
• Impola U, Turpeinen H, Alakulppi N, et al. Donor haplotype B of NK KIR receptor reduces the relapse risk in HLA-Identical sibling hematopoietic stem cell transplantation of AML patients. Front Immunol. 2014 Aug 25;5:405.
   PubMedGoogle Scholar
• Krieger E, Qayyum R, Keating A, et al. Increased donor inhibitory KIR with known HLA interactions provide protection from relapse following HLA matched unrelated donor HCT for AML. Bone Marrow Transplant. 2021 Nov;56(11):2714–2722. doi: 10.1038/s41409-021-01393-9
   PubMed Web of Science ®Google Scholar
• Rathmann S, Glatzel S, Schönberg K, et al. Expansion of NKG2A−LIR1− natural killer cells in HLA-Matched, killer cell immunoglobulin-like receptors/HLA-Ligand mismatched patients following hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2010 Apr;16(4):469–481. doi: 10.1016/j.bbmt.2009.12.008
   PubMed Web of Science ®Google Scholar
• Symons HJ, Leffell MS, Rossiter ND, et al. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2010 Apr;16(4):533–542. doi: 10.1016/j.bbmt.2009.11.022
   PubMed Web of Science ®Google Scholar
• Bastos-Oreiro M, Anguita J, Martínez-Laperche C, et al. Inhibitory killer cell immunoglobulin-like receptor (iKIR) mismatches improve survival after T-cell-repleted haploidentical transplantation. Eur J Haematol. 2016 May;96(5):483–491. doi: 10.1111/ejh.12616
   PubMed Web of Science ®Google Scholar
• Escudero A, Martínez-Romera I, Fernández L, et al. Donor KIR Genotype Impacts on Clinical Outcome after T Cell–Depleted HLA Matched Related Allogeneic Transplantation for High-Risk Pediatric Leukemia Patients. Biol Blood Marrow Transplant. 2018 Dec;24(12):2493–2500. doi: 10.1016/j.bbmt.2018.08.009
   PubMed Web of Science ®Google Scholar
• McQueen KL, Dorighi KM, Guethlein LA, et al. Donor–recipient combinations of group a and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-Matched, sibling donor hematopoietic cell transplantation. Hum Immunol. 2007 May;68(5):309–323. doi: 10.1016/j.humimm.2007.01.019
   PubMed Web of Science ®Google Scholar
• Fein JA, Shouval R, Krieger E, et al. KIR-HLA interactions lack clinical utility in matched unrelated donor transplantation for AML: an analysis of the CIBMTR and DRST registries. Blood. 2021;138(Supplement 1):419–419. doi: 10.1182/blood-2021-149935
   Google Scholar
• Dubreuil L, Chevallier P, Retière C, et al. Relevance of polymorphic KIR and HLA class I genes in NK-Cell-based immunotherapies for adult leukemic patients. Cancers. 2021 Jul 27;13(15):3767. doi: 10.3390/cancers13153767
   PubMed Web of Science ®Google Scholar
• Koenecke C, Shaffer J, Alexander SI, et al. NK cell recovery, chimerism, function, and recognition in recipients of haploidentical hematopoietic cell transplantation following nonmyeloablative conditioning using a humanized anti-CD2 mAb, medi-507. Exp Hematol. 2003 Oct;31(10):911–923. doi: 10.1016/S0301-472X(03)00224-8
   PubMed Web of Science ®Google Scholar
• Bachanova V, Cooley S, Defor TE, et al. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood. 2014 Jun 19;123(25):3855–3863. doi: 10.1182/blood-2013-10-532531
   PubMed Web of Science ®Google Scholar
• Curti A, Ruggeri L, D’Addio A, et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood. 2011 Sep 22;118(12):3273–3279. doi: 10.1182/blood-2011-01-329508
   PubMed Web of Science ®Google Scholar
• Romee R, Rosario M, Berrien-Elliott MM, et al. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Sci Transl Med. 2016 Sep 21;8(357):357ra123. doi: 10.1126/scitranslmed.aaf2341
   PubMed Web of Science ®Google Scholar
• Romee R, Schneider SE, Leong JW, et al. Cytokine activation induces human memory-like NK cells. Blood. 2012 Dec 6;120(24):4751–4760. doi: 10.1182/blood-2012-04-419283
   PubMed Web of Science ®Google Scholar
• Berrien-Elliott MM, Cashen AF, Cubitt CC, et al. Multidimensional analyses of donor memory-like NK cells reveal new associations with response after adoptive immunotherapy for leukemia. Cancer Discov. 2020 Dec;10(12):1854–1871. doi: 10.1158/2159-8290.CD-20-0312
   PubMed Web of Science ®Google Scholar
• Leong JW, Chase JM, Romee R, et al. Preactivation with IL-12, IL-15, and IL-18 induces CD25 and a functional high-affinity IL-2 receptor on human cytokine-induced memory-like natural killer cells. Biol Blood Marrow Transplant. 2014 Apr;20(4):463–473. doi: 10.1016/j.bbmt.2014.01.006
   PubMed Web of Science ®Google Scholar
• Shapiro RM, Birch GC, Hu G, et al. Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J Clin Invest. 2022 Jun 1;132(11). doi: 10.1172/JCI154334
   Web of Science ®Google Scholar
• Dong H, Ham JD, Hu G, et al. Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia. Proc Natl Acad Sci U S A. 2022 Jun 21;119(25):e2122379119. doi: 10.1073/pnas.2122379119
   PubMedGoogle Scholar
• Peltier D, Reddy P. Non-Coding RNA Mediated Regulation of Allogeneic T Cell Responses After Hematopoietic Transplantation. Front Immunol. 2018 Jun 15;9:1110. doi: 10.3389/fimmu.2018.01110
   PubMed Web of Science ®Google Scholar
• Zeiser R, Youssef S, Baker J, et al. Preemptive HMG-CoA reductase inhibition provides graft-versus-host disease protection by th-2 polarization while sparing graft-versus-leukemia activity. Blood. 2007 Dec 15;110(13):4588–4598. doi: 10.1182/blood-2007-08-106005
   PubMed Web of Science ®Google Scholar
• Uhl FM, Chen S, O’Sullivan D, et al. Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans. Sci Transl Med. 2020 Oct 28;12(567). doi: 10.1126/scitranslmed.abb8969
   PubMed Web of Science ®Google Scholar
• Li J-M, Petersen CT, Li J-X, et al. Modulation of immune checkpoints and graft-versus-leukemia in allogeneic transplants by antagonizing vasoactive intestinal peptide signaling. Cancer Res. 2016 Dec 1;76(23):6802–6815. doi: 10.1158/0008-5472.CAN-16-0427
   PubMed Web of Science ®Google Scholar
• Oravecz-Wilson K, Rossi C, Zajac C, et al. ATG5-dependent autophagy uncouples T-cell proliferative and effector functions and separates graft-versus-host disease from graft-versus-Leukemia. Cancer Res. 2021 Feb 15;81(4):1063–1075. doi: 10.1158/0008-5472.CAN-20-1346
   PubMed Web of Science ®Google Scholar
• Ghosh A, Holland AM, Dogan Y, et al. PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHD. Cancer Res. 2013 Aug 1;73(15):4687–4696. doi: 10.1158/0008-5472.CAN-12-4699
   PubMed Web of Science ®Google Scholar
• Gambacorta V, Beretta S, Ciccimarra M, et al. Integrated Multiomic Profiling Identifies the Epigenetic Regulator PRC2 as a Therapeutic Target to Counteract Leukemia Immune Escape and Relapse. Cancer Discov. 2022 Jun 2;12(6):1449–1461. doi: 10.1158/2159-8290.CD-21-0980
   PubMed Web of Science ®Google Scholar
• Ho JNGH, Schmidt D, Lowinus T, et al. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation. Blood. 2022 Sep 8;140(10):1167–1181. doi: 10.1182/blood.2022016082
   PubMed Web of Science ®Google Scholar
• Baron F, Labopin M, Tischer J, et al. Human leukocyte antigen-haploidentical transplantation for relapsed/refractory acute myeloid leukemia: better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients ≥55 years of age. Am J Hematol. 2022 Aug;97(8):1065–1074. doi: 10.1002/ajh.26627
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015 Aug 20;126(8):1033–1040. doi: 10.1182/blood-2015-04-639831
   PubMed Web of Science ®Google Scholar